Tasly Pharmaceuticals and Mauna Kea Form JV to Commercialize Cellvizio in China
China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...
China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...
China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...
Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB...
Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB...
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...
Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its...
The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...
Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...
China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD...
China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...
China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...
China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with...
China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus...
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...
Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a...
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...